[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629373":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":74,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PRP injections","EXPERIMENTAL","Single arm receiving autologous platelet-rich plasma injections at Day 0, Day 14 (±1), and Day 28 (±1), with follow-up at Months 3 and 6.",[13],"Biological: Autologous Platelet-Rich Plasma (PRP) Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Autologous Platelet-Rich Plasma (PRP) Injection","At each injection visit (Day 0, Day 14 ±1, Day 28 ±1), venous blood is collected and processed to obtain autologous PRP using a standardized preparation system. PRP is injected under endoscopic guidance into the superior nasal septum mucosa near the olfactory cleft, up to a total volume of 4 mL per visit. Participants are monitored after each injection and adverse events are recorded.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"MAxime FIEUX, Dr","CONTACT","0033 4 72 66 64 15","+33","maxime.fieux@chu-lyon.fr",[29],{"facility":30,"status":20,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Hôpital Lyon Sud","Pierre-Bénite","69310","France","FR",{"type":36,"coordinates":37},"Point",[38,39],4.82424,45.70359,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":25,"phoneExt":26,"email":27},"Maxime FIEUX, Dr",{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100629373","pandora-evaluation-of-platelet-rich-plasma-in-non-tumoural-odour-disorders-a-descriptive-pilot-study-100629373",false,"NCT07473830","PANDORA: Evaluation of Platelet-rich Plasma in Non-tumoural Odour Disorders: a Descriptive Pilot Study.","PANDORA","Inclusion Criteria\n\n* Adults with persistent (\\>6 months) non-tumoural olfactory dysfunction: age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT).\n* Objective olfactory impairment confirmed by Sniffin' Sticks Test (TDI ≤ 30.5\u002F48).\n* MRI within the last 6 months after onset excluding tumoural etiology or central cause.\n* Normal nasal endoscopy.\n* Affiliated to a social security system (or equivalent).\n* Written informed consent.\n\nExclusion Criteria\n\n* Inflammatory rhinosinus disease (e.g., nasal polyposis) or granulomatosis with polyangiitis.\n* Coagulation disorder.\n* Brain radiotherapy history or ongoing chemotherapy.\n* Olfactory disorder temporally linked to SARS-CoV-2 infection (delay \\\u003C1 month).\n* History of sinus or skull base surgery (except septoplasty\u002Fturbinoplasty\u002Frhinoseptoplasty).\n* Therapeutic-dose anticoagulants.\n* Refusal to discontinue chronic NSAID use if applicable.\n* Pregnancy\u002Flabor\u002Fbreastfeeding.\n* Vulnerable persons (deprived of liberty; legal protection; etc.).\n* Participation in another interventional study with ongoing exclusion period.","ALL","18 Years","99 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"NA","This is a prospective, single-center, single-arm, non-comparative descriptive pilot study evaluating autologous platelet-rich plasma (PRP) injections in adults with persistent (\\>6 months) non-tumoural olfactory dysfunction, either age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT). Participants receive three PRP injections over 4 weeks (Day 0, Day 14, Day 28), with follow-up visits at Month 3 and Month 6 after the first injection. Olfactory function is assessed using the Sniffin' Sticks Test (TDI score). Patient-reported outcomes include SNOT-22 and a visual analog scale (VAS) for perceived olfactory impairment. Safety is assessed through adverse event collection.",[64,65,66],"Olfactory Dysfunction","Post-traumatic Olfactory Dysfunction","Age-related Degenerative Olfactory Dysfunction",[68,69,70,71,72,73],"Platelet-rich plasma","PRP","Sniffin' Sticks","Olfactory cleft","Hyposmia","Anosmia","NOT_YET_RECRUITING","2026-03-17",{"date":77,"type":78},"2026-03-20","ACTUAL",{"date":80,"type":58},"2026-05",{"date":82,"type":58},"2028-05",{"name":5,"class":6},1]